Cirium: Radical Shifts in US Flight Schedules This Summer Reveal Why Airlines Need New Planning Tools to Stay Ahead of the Curve
The new DiioTM Schedule Snapshot offering released by Cirium, the aviation analytics firm, reveals how planning by the major US airlines changed over the summer, with 20% of flights being removed from their schedule for September.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005581/en/
The September flight schedules as published by American Airlines, Delta Air Lines, Southwest, and United Airlines initially in May compared with the revised plan published four months later. (Graphic: Business Wire)
At the start of May 2021, the plan for what carriers would fly in September was more or less in line with pre-pandemic levels in 2019. By the time they came to fly the September schedule, American Airlines, Delta Air Lines, Southwest and United Airlines had significantly cut back their flights.
Airlines are now making major changes to the way they schedule flights—publishing or removing them much closer to the date of departure as they struggle with the uncertainties brought on by the pandemic.
Prior to the pandemic schedules would remain fairly stable over a season, with few changes—positive or negative—as the plan was refined.
Only 3% of flights were removed from the September schedule in 2019 compared with the plan published in May that year.
The new Diio Schedule Snapshot web-based tool enables airlines and airports to track changes to the flights being scheduled at different points in time. It provides much more detail on schedule changes than has been done in the past.
“In today's environment where travel restrictions and vaccination programs are significantly impacting flight schedules, airlines have had to adapt and issue changes to their schedules frequently and much closer to the day of departure. The traditional methods used to analyze demand need to be more dynamic,” said Kevin O’Toole, Chief Strategy Officer at Cirium.
“Using Diio Schedules Snapshot, airlines and airports can understand schedule changes over time, optimize future schedules, build stronger models for planning and revenue management, and optimize yield through trend analysis.”
The analysis of the major US airlines evidences the radical shift in the summer flight schedule and the impact that the pandemic has had on the variance in airline planning year-over-year.
Understanding and comparing changes to the published flight schedule over time as it gets closer to actual departure, enables analysts to stay ahead of the curve, and provides new insights for planning and revenue management.
Reviewing historical data by publication date also provides insights on airline and airport strategies in an uncertain world.
Diio Schedule Snapshot is part of the unrivaled Cirium Diio suite of products for airline planning. The suite includes Diio Mi, SRS AnalyserTM, Cirium Scenario Planner, and Diio Traffic and Fares.
The new tool integrates with Cirium Diio Mi or SRS Analyser and is the first of many more new tools in the Cirium pipeline to help airlines optimize their schedules and find new revenue opportunities.
More information on Diio Schedule Snapshot can be found at https://cirium.com/products/views/diio-schedule-snapshot
-End-
For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005581/en/
Contact information
For media enquiries please contact:
Mike Arnot, Juliett Alpha via cirium@juliettalpha.com
or the Cirium media team at media@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth26.1.2026 11:15:00 EET | Press release
IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/ From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO) Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO. As part of the transition, Mikko Välimäki steps down from his commercial role following a successful tenure as Co-CEO. He will continue to support the company as an advisor until 31 March 2026 to ensure continuity and a smooth transition. “Our dual CEO approach has served IQM well over the past two years, and I want to thank Mikko Välimäki for his significan
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 10:00:00 EET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 09:58:00 EET | Press release
Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019 and 2022, respectively – and reflects increasing investor demand for a specialist global credit platform with expertise across the full spectrum of the asset class. A refreshed logo and new website domain accompany the brand alignment, and from this week Alcentra branded funds start to take on the BSP name.1 Overall, Franklin Templeton’s alternative credit platform – which also includes direct lender Apera – is on track to exceed $100 billion in AUM in 2026. According to new research also published tod
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 09:00:00 EET | Press release
Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Head CP Sourcing at Syngenta. "This tailored approach allows us to make meaningful progress toward our carbon reduction targets for Syngenta AG while m
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 09:00:00 EET | Press release
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide.” Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results In the fourth quarter of 2025, Samsung Bioepis achieved a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
